1. Eight-Year Outcomes of Patients With Reduced Left Ventricular Ejection Fraction Who Underwent Transcatheter Aortic Valve Replacement With a Self-Expanding Bioprosthesis.
- Author
-
De Felice F, Paolucci L, Musto C, Nazzaro MS, Chin D, Stio R, Pennacchi M, Adamo M, Chizzola G, Massussi M, Giannini C, Angelillis M, De Carlo M, Gorla R, Bedogni F, Bellini B, Montorfano M, Bruschi G, Merlanti B, Ferrara E, Poli A, Regazzoli D, Palmerini T, Iadanza A, Nicolini E, Toselli M, De Marco F, and Gabrielli D
- Subjects
- Humans, Male, Female, Aged, 80 and over, Aged, Ventricular Dysfunction, Left physiopathology, Heart Valve Prosthesis, Italy epidemiology, Cause of Death trends, Follow-Up Studies, Patient Readmission statistics & numerical data, Treatment Outcome, Prosthesis Design, Time Factors, Prospective Studies, Transcatheter Aortic Valve Replacement, Stroke Volume physiology, Aortic Valve Stenosis surgery, Aortic Valve Stenosis physiopathology, Bioprosthesis
- Abstract
Data deriving from patients who underwent TAVR between 2007 and 2017 in 13 Italian centers were prospectively collected. Patients were stratified in those with normal LVEF and reduced LVEF. The latter was further classified according to ischemic or nonischemic etiology. The primary end point was a composite of all-cause death and rehospitalizations; the secondary end points were the isolated composers of the primary end point and cardiac death. Overall, 2,626 patients were included in the analysis: 68.1% with normal LVEF and 31.9% with reduced LVEF. At 8 years, reduced LVEF was significantly associated with the primary end point (adjusted hazard ratio 1.17, 95% confidence interval 1.06 to 1.29). Consistent findings were evident for the composite end point. No differences in these trends were found at the 30-day landmark analyses. Compared with nonischemic etiology, ischemic reduced LVEF was associated with an increased risk of cardiac death (adjusted hazard ratio 1.43, 95% confidence interval 1.02 to 2.02). In conclusion, patients with reduced LVEF who underwent TAVR are exposed to a progressively increased risk of death and rehospitalizations, even at very long-term follow-up., Competing Interests: Declaration of competing interest CG, MA, and MDC received speaker fees from Medtronic; FB received consultant/proctor fees from Medtronic; MM received consultant fees from Abbott, Boston, Kardia and Medtronic; TP received lectures fees from Medtronic, Edwards and Abbott. The remaining authors have no competing interest to declare., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF